Erythropoietin Treatment Decreases Cardiovascular Morbidity and Mortality in Capd Patients

Report on management of renal failure in Europe, XXII, 1991. Nephrol Dial Transplant 1992; 7(Suppl) S5–S48.

Excerpts from the United States Renal Data System. 1994 annual data report. Am J Kidney Dis 1994; 24(Suppl 2) Sl–181.

Bloembergen W. , Port F. , Wolfe R. , Eggers P. Changes in causes of death in patients treated with dialysis. J Am Soc Nephrol 1992; 3: 355.

Colemann G. Hemodynamics of uremic anemia. Circulation 1972; 45: 510–11.

Varat M. , Adolph R. , Fowler N. Cardiovascular effects of anemia. Am Heart J 1972; 83: 415.

Eschbach J. , Egrie J. , Downing M. , Browne J. , Adamson J. Correction of the anemia of end -stage renal disease with recombinant human erythropoietin. N Engl J Med 1987; 316: 73–8.

Bommer J. , Alexiou C. , Muller-Buhl U. , Eifert J. , Ritz E. Recombinant human erythropoietin therapy in haemo dialysis patients. Dose determination and clinical experience. Nephrol Dial Transplant 1987; 2: 238–42.

Casati S. , Passerini P. , Campise M. , Graziani G. , Cesana B. , Merisic M. , Ponticelli C. Benefits and risks of protracted treatment with human recombinant erythropoietin in patients having haemodialysis. Br Med J 1987; 295: 1017–20.

Eschbach J.W. , Kelly M.R. , Haley N.R. Treatment of the anemia of progressive renal failure with recombinant human erythropoietin. N Engl J Med 1989; 321: 158–63.

Schaefer R.M. , Horl W.H. , Massry S.G. Treatment of renal anemia with recombinant human erythropoietin. Am J Nephrol 1989; 9: 353–62.

Ponticelli C. , Casati S. Correction of anemia with recombinant human erythropoietin. Nephron 1989; 52:201–8.

Miranda B. , Selgas R. , Riñon C. , Fernandez-Zamorano A. Treatment of anemia with human recombinant erythropoietin in CAPD patients. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in peritoneal dialysis. Peritoneal Dialysis Bulletin Inc., 1990; 6: 296–301.

Bajo M.A. , Selgas R. , Miranda B. , Fernandez-Zamorano A. Medium term response to H-R-erythropoietin in CAPD patients: the influence of erythropoietin plasmatic levels and the effects on peritoneal transport capacity. In: Khanna R. , Nolph K.D. , Prowant B.F. , Twardowski Z.J. , Oreopoulos D.G. , eds. Advances in peritoneal dialysis. Peritoneal Dialysis Bulletin Inc., 1991; 7: 296–300.

Korbet S.M. Anemia and erythropoietin in hemodialysis and continuous ambulatory peritoneal dialysis. Kidney Int 1993; 43(Suppl): 111–19.

Watson A. , Swartz R. , Zimmerman S. Multicenter trial of erythropoietin in patients on peritoneal dialysis. J Am Soc Nephrol 1995; 5: 1517–29.

Low I. , Grutzmacher P. , Bergmann M. , Schoeppe W. Echocardiographic findings in patients on maintenance hemodialysis substituted with recombinant human erythropoietin. Clin Nephrol 1989; 31: 26–30.

Teruel J.L. , Pascual J. , Jimenez M. , Liaño F. Hemodynamic changes in hemodialyzed patients during treatment with recombinant human erythropoietin. Nephron 1991; 58:135–7.

Martinez-Vea A. , Bardají A. , Garcia C. , Ridao C. Long-term effects of correction of anemia with recombinant erythropoietin in aged patients on hemodialysis. Am J Kidney Dis 1992; 19: 353–7.

Fellner S. , Lang R. , Neumann A. , Korcarz C. , Borow K. Cardiovascular consequences of correction of the anemia ofrenal failure with erythropoietin. Kidney Int 1993; 44: 1309–15.

London G. , Zins B. , Pannier B. Vascular changes in hemodialysis patients in response to recombinant human erythropoietin. Kidney Int 1989; 36: 878–82.

Tagawa H. , Nagano M. , Saito H. Echocardiographic findings in hemodialysis patients treated with recombinant human erythropoietin. Proposal for a hematocrit most beneficial to hemodynamics. Clin Nephrol 1991; 35: 35–8.

Cannella G. , La Canna G. , Sandrini M. , Gaggiotti M. , Nordio G. , Maiorca R. Reversal of left ventricular hypertrophy following recombinant human erythropoietin treatment of anaemia dialyzed uraemic patients. Nephrol Dial Transplant 1991; 6: 31–7.

Pascual J. , Teruel J.L. , Moya J.L. , Liaño F. , JimenezMena M. , Ortuño J. Regression of left ventricular hypertrophy after partial correction of anemia with erythropoietin in patients on hemodialysis: a prospective study. Clin Nephrol 1991; 35: 280–7.

Low-Friedrich I. , Grutzmacher P. , Marz W. , Bergmann M. , Schoeppe W. Therapy with recombinant human erythropoietin reduces cardiac size and improves heart function in chronic hemodialysis patients. Am J Nephrol 1991; 11: 54–60.

Goldberg N. , Lundin A.P. , Delano B. Changes in left ventricular size, wall thickness and function in anemic patients treated with recombinant human erythropoietin. Am Heart J 1992; 124: 424–7.

MacDougal1 I.C. , Lewis N.P. , Saunders M.J. , Cochlin D.L. , Davies M.E. , Hut ton R.D. Long-term cardiorespiratory effects of amelioration of renal anaemia by erythropoietin. Lancet 1990; 335: 489–93.

Wizemann V. , Kaufmann J. , Kramer W. Effects of erythropoietin on ischemia tolerance in anemic hemodialysis patients with confirmed coronary artery disease. Nephron 1992; 62: 161–5.

Samtleben W. , Baldamus C.A. , Bommere J. Blood pressure changes during treatment with recombinant human erythropoietin. Contrib Nephrol 1988; 66: 114–22.

Sundal E. , Kaeser U. Correction of anemia of chronic renal failure with recombinant human erythropoietin: safety and efficacy of one year's treatment in an European multicenter study of 150 haemodialysis-dependent patients. Nephrol Dial Transplant 1989; 4: 979–87.

Raine A.E. , Roger S.D. Effects of erythropoietin on blood pressure. Am J Kidney Dis 1991; 18: 76–83.

Harnett J.D. , Huong L.E. Cardiovascular effects of erythropoietin. Dial Transplant 1993; 22: 536–40.

Deschodt G. , Granolleras C. , Alsabadani B. Changes in cardiac output, blood pressure and peripheral resistance following treatment of renal anemia by recombinant human erythropoietin. Nephrol Dial Transplant 1988; 3: 494–5.

Satoh K. , Masuda T. , Ikeda Y. Hemodynamic changes by recombinant erythropoietin therapy in hemodialyzed patients. Hypertension 1990; 15: 262–6.

Eschbach J.W. , Aquiling T. , Haley N.R. , Fan M.H. , Blagg C.R. The long-term effects of recombinant human erythropoietin on the cardiovascular system. Clin Nephrol 1992; 38(Suppl): 98–103.

Eschbach J.W. Erythropoietin: the promise and the facts. Kidney Int 1994; 45(Suppl 44): 70–6.

McMahon L.P. , Dawborn J.K. Subjective quality of life assessment in hemodialysis patients at different levels of hemoglobin following use of recombinant human erythropoietin. Am J Nephrol 1992; 2: 162–9.

Valderrabano F. , Moreno F. , Aracil F.J. A controlled study on the effect of erythropoietin on the quality of life of elderly haemodialysis patients. J Am Soc Nephrol 1992; 3: 432.

Nonnaast-Danie I.B. , Deschodt G. , Brunkhorst R. , Creutzig A. , Bahlmann J. , Shaldon S. Long-term effects of treatment with recombinant human erythropoietin on haemodynamics and tissue oxygenation in patients with renal anaemia. Nephrol Dial Transplant 1990; 5: 444.

Foley R.N. , Parfrey P.S. , Harnett J.D. Clinical and echocardiographic disease in patients starting end-stage renal disease therapy. Kidney Int 1995; 47: 186–92.

Hutchinson T.A. , Duncan M.B. , Thomas C.D. , MacGibbon B. Predicting survival in adults with end-stage renal failure: an age-equivalence index. Ann Intern Med 1982; 96: 417–23.

Collins A.J. , Ma J.Z. , Umen A. , Keshaviah P. Urea index and other predictors of hemodialysis patient survival. Am J Kidney Dis 1994; 23: 272–82.

Gomez-Farias M.A. , McClellan W. , Soucie J. , Mitch W. A prospective comparison of methods for determining if cardiovascular disease is a predictor of mortality in dialysis patients. Am J Kidney Dis 1994; 23: 382–8.

Maiorca R. , Vonesh E. , Cancarini G.C. A six-year comparison of patient and technique survivals in CAPD and HD. Kidney Int 1988; 34:518–24.

Brown J.H. , Hunt L.P. , Vites N.P. , Short C.D. , Gokal R. , Mallick N.P. Comparative mortality from cardiovascular disease in patients with chronic renal failure. Nephrol Dial Transplant 1994; 9: 1136–42.

Churchill D.N. , for the Canadian Hemodialysis Morbidity Study Group. Results of the Canadian Morbidity Study in end-stage renal disease patients treated by hemodialysis. Semin Nephrol 1990; 10(Suppl 1): 66–72.

Churchill D.N. , Taylor D.W. , Cook R.J. Canadian Hemodialysis Morbidity Study. Am J Kidney Dis 1992; 19: 214–34.

Wolfe R.A. , Port F.K. , Hawthorne V.M. , Guire K.E. A comparison of survival among dialysis therapy of choice. In center hemodialysis versus continuous ambulatory peritoneal dialysis at home. Am J Kidney Dis 1990; 15: 433–40.

Held P.J. , Garcia J.R. , Pauly M.V. , Cahn M.A. Price of dialysis, unit staffing and length of dialysis treatment. Am J Kidney Dis 1990; 15: 441–50.

Lowrie E.G. , Lew N.L. Death risk in hemodialysis patients: the predictive value of commonly measured variables and an evaluation of death rate differences between facilities. Am J Kidney Dis 1990; 15: 458–82.

Iseki K. , Kawazoe N. , Osawa A. , Fukiyama K. Survival in dialysis patients in Okinawa, Japan (1971–1990). Kidney Int 1993; 43: 404–9.

Maiorca R. , Cancarini G.C. , Brunori G. , Camerini C. , Manili L. Morbidity and mortality of CAPD and hemodialysis. Kidney Int 1993; 43: (Suppl 40): 4–15.

Firanek C.A. , Vonesh E.F. , Korbet S.M. Patients and technique survival among an urban population of peritoneal dialysis patients: an 8 year experience. Am J Kidney Dis 1991; 18: 91–6.

Vollmer W.M. , Wahl P.W. , Blagg C.R. Survival with dialysis and transplantation in patients with endstage renal disease. N Engl J Med 1983; 308: 1553–8.

Nagai T. , Akizawa T. , Nakashima Y. Effects of rHuEpo on cellular proliferation and endothelin-1 production in cultured endothelial cells. Nephrol Dial Transplant 1995; 10: 1814–19.